Aarti Pharmalabs Ltd
Q1 FY27, unaudited
- Revenue
- ₹534.59 Cr
- Profit after tax
- ₹71.31 Cr
As filed with the exchange, standalone basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 534.59 | +42.44% | 1,797.55 |
| Other income | 2.93 | +83.72% | 15.32 |
| Total income | 537.52 | +42.61% | 1,812.87 |
| Employee benefit expense | 49.77 | +21.34% | 170.48 |
| Finance costs | 12.87 | +89.46% | 46.90 |
| Depreciation & amortisation | 30.03 | +31.95% | 104.30 |
| Total expenses | 441.30 | +42.48% | 1,575.84 |
| Profit before tax | 96.22 | +43.25% | 234.24 |
| Tax expense | 24.92 | +56.19% | 58.04 |
| Profit after tax | 71.31 | +39.21% | 176.20 |
| Total comprehensive income | 73.13 | +39.89% | 172.25 |
| Earnings per share, basic | ₹7.87 | ₹19.44 |
|---|---|---|
| Earnings per share, diluted | ₹7.86 | ₹19.42 |
Earnings call
Q4 FY26Aarti Pharmalabs reported Q4 FY2026 standalone revenue of Rs.580 Crores, up 9% year-on-year, while full year FY2026 revenue was Rs.1798 Crores against Rs.1771 Crores in FY2025. EBITDA and profit after tax declined both for the quarter and the full year compared to the previous year, with management citing a net foreign exchange loss and cost pressures from the West Asia conflict. Management discussed segment performance across Xanthine derivatives, API/Intermediates and CDMO/CMO, and outlined capex plans and capacity expansions at Tarapur and Atali for the coming year.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Filings
12 shown · 39 published by the exchange
18 Aug 2026
Filing17 Aug 2026
17 Aug 2026
Transcript10 Aug 2026
10 Aug 2026
Presentation09 Aug 2026
Filing07 Aug 2026
07 Aug 2026
07 Aug 2026
07 Aug 2026
03 Aug 2026
28 Jul 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 18 Aug 2026.